GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. (June 2017) - Schuster, S.J.; Bishop, M.R.; Tam, C.; Waller, E.K.; Borchmann, P.; Mcguirk, J.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.; Fleury, I.; Bachanova, V.; et al.